Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study
Abstract Predictive value of metabolic syndrome for prostate cancer risk is not clear. We aimed to assess the association between metabolic syndrome and its components with prostate cancer incidence. The primary outcome was prostate cancer incidence, i.e., incidence rate ratios and adjusted cumulati...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-85501-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594740147650560 |
|---|---|
| author | Shing Fung Lee Maja Nikšić Miguel Angel Luque-Fernandez |
| author_facet | Shing Fung Lee Maja Nikšić Miguel Angel Luque-Fernandez |
| author_sort | Shing Fung Lee |
| collection | DOAJ |
| description | Abstract Predictive value of metabolic syndrome for prostate cancer risk is not clear. We aimed to assess the association between metabolic syndrome and its components with prostate cancer incidence. The primary outcome was prostate cancer incidence, i.e., incidence rate ratios and adjusted cumulative incidence curves derived from flexible parametric survival models. Adjusted cumulative incidence curves were derived using a flexible survival parametrical modeling framework. We analysed UK Biobank data including 242,349 adult males, recruited during 2006–2010 and followed up until 2021, during which 6,467 (2.7%) participants were diagnosed with prostate cancer. Our findings indicate that metabolic syndrome, as a whole, was not associated with prostate cancer risk (incidence rate ratios, 1.07; 95% confidence interval, 0.94–1.22). However, specific components such as hypertension and obesity increased the risk (incidence rate ratios, 1.22; 95% confidence interval, 1.03–1.44 and incidence rate ratios, 1.24; 95% confidence interval, 1.05–1.46, respectively). Other components, such as prediabetes/diabetes and low cholesterol, were associated with a reduced risk (incidence rate ratios, 0.80; 95% confidence interval, 0.67–0.94 and incidence rate ratios, 0.82; 95% confidence interval, 0.69–0.97, respectively), while hyperlipidaemia showed no significant effect (incidence rate ratios, 1.07; 95% confidence interval, 0.93–1.24). Further research is needed to understand the underlying mechanisms behind these relationships. Prostate cancer prevention strategies might benefit from targeting modifiable risk factors, particularly hypertension and obesity. |
| format | Article |
| id | doaj-art-0cb91cc28ad94dc7a45ab39b8ccb67fd |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-0cb91cc28ad94dc7a45ab39b8ccb67fd2025-01-19T12:19:59ZengNature PortfolioScientific Reports2045-23222025-01-0115111010.1038/s41598-025-85501-5Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort studyShing Fung Lee0Maja Nikšić1Miguel Angel Luque-Fernandez2Department of Radiation Oncology, National University Cancer Institute, National University HospitalCentre for Health Services Studies, University of KentDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical MedicineAbstract Predictive value of metabolic syndrome for prostate cancer risk is not clear. We aimed to assess the association between metabolic syndrome and its components with prostate cancer incidence. The primary outcome was prostate cancer incidence, i.e., incidence rate ratios and adjusted cumulative incidence curves derived from flexible parametric survival models. Adjusted cumulative incidence curves were derived using a flexible survival parametrical modeling framework. We analysed UK Biobank data including 242,349 adult males, recruited during 2006–2010 and followed up until 2021, during which 6,467 (2.7%) participants were diagnosed with prostate cancer. Our findings indicate that metabolic syndrome, as a whole, was not associated with prostate cancer risk (incidence rate ratios, 1.07; 95% confidence interval, 0.94–1.22). However, specific components such as hypertension and obesity increased the risk (incidence rate ratios, 1.22; 95% confidence interval, 1.03–1.44 and incidence rate ratios, 1.24; 95% confidence interval, 1.05–1.46, respectively). Other components, such as prediabetes/diabetes and low cholesterol, were associated with a reduced risk (incidence rate ratios, 0.80; 95% confidence interval, 0.67–0.94 and incidence rate ratios, 0.82; 95% confidence interval, 0.69–0.97, respectively), while hyperlipidaemia showed no significant effect (incidence rate ratios, 1.07; 95% confidence interval, 0.93–1.24). Further research is needed to understand the underlying mechanisms behind these relationships. Prostate cancer prevention strategies might benefit from targeting modifiable risk factors, particularly hypertension and obesity.https://doi.org/10.1038/s41598-025-85501-5Prostate CancerMetabolic SyndromeRisk FactorsLifestyleDietExercise |
| spellingShingle | Shing Fung Lee Maja Nikšić Miguel Angel Luque-Fernandez Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study Scientific Reports Prostate Cancer Metabolic Syndrome Risk Factors Lifestyle Diet Exercise |
| title | Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study |
| title_full | Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study |
| title_fullStr | Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study |
| title_full_unstemmed | Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study |
| title_short | Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study |
| title_sort | understanding the role of metabolic syndrome in prostate cancer risk a uk biobank prospective cohort study |
| topic | Prostate Cancer Metabolic Syndrome Risk Factors Lifestyle Diet Exercise |
| url | https://doi.org/10.1038/s41598-025-85501-5 |
| work_keys_str_mv | AT shingfunglee understandingtheroleofmetabolicsyndromeinprostatecancerriskaukbiobankprospectivecohortstudy AT majaniksic understandingtheroleofmetabolicsyndromeinprostatecancerriskaukbiobankprospectivecohortstudy AT miguelangelluquefernandez understandingtheroleofmetabolicsyndromeinprostatecancerriskaukbiobankprospectivecohortstudy |